While the changes in lipid parameters are smaller compared to those elicited by LY2405319 or PF-05231023, pegbelfermin is the first FGF21 analog to demonstrate beneficial hepatic effects in NASH patients, with daily administration yielding approximately a 30% relative reduction in liver fat content. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.